Legend Biotech Corporation (LEGN)

Legend Biotech Corporation's Q·Score is 6.4/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $48.48 is 174% above current price. Key area to monitor: currently unprofitable (-7% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for LEGN is $48.48, based on ratings from 14 Wall Street analysts. This is 174.4% above the current price of $17.67. Price targets are forward-looking estimates and not guarantees of future performance.

Legend Biotech Corporation (LEGN) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 16.8×. The consensus analyst price target of $48.48 is 174% above the current price.

Legend Biotech Corporation's next earnings report is expected on approximately November 11, 2026.

Legend Biotech Corporation has a net profit margin of -7.2%, indicating the company is currently operating at a net loss. Its gross margin stands at 56.6%, indicating a high-margin business model.

Legend Biotech Corporation is reporting strong year-over-year growth of 51.9%.

Legend Biotech Corporation has a debt-to-equity ratio of 0.23×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 3.04×, indicating comfortable short-term liquidity.